In order to demonstrate the proof of concept that inhibition of EphA10 specifically expressed in breast cancers induces an anti-tumor effect, we generated a neutralizing monoclonal antibody against EphA10 and then analyzed the therapeutic effect in a xenograft mouse model. Here, EPHA10 is linked to breast carcinoma.